Webinar, Interview, Fireside Chat
In Search for a Cure: Are We Nearing a Treatment for COVID-19?
- First wave of infections is projected to persist through July and August, with a second wave expected to emerge in the fall due to continued transmissibility and a lag period before current infections in young populations result in increased hospitalizations and deaths among vulnerable groups.
- If transmission chains are not interrupted, continued infection of vulnerable individuals by younger demographics is predicted to cause surges in hospitalizations and deaths, potentially necessitating a return to lockdowns in severely affected localities despite anticipated political pushback.
- Vaccine development timelines anticipate Phase three trials commencing in July or a few weeks from now, involving approximately 30,000 participants across over 100 global sites, with the second dose administered in August and efficacy results determined by mid-to-late fall or early winter.
- Pfizer projects data supporting safety and efficacy to be available in September, potentially leading to FDA approval in October, with initial availability of tens of millions of doses in late 2020 rising to 100 million by year-end and up to 1 billion doses available globally in 2021.
- Broader industry expectations suggest hundreds of millions of vaccine doses could be ready by the beginning of 2021 and as many as one billion by the end of the year, contingent on no significant manufacturing disruptions and successful resolution of logistics challenges such as minus 80-degree storage requirements in Africa.
- Vaccine efficacy targets for achieving widespread societal immunity and a return to normalcy are estimated at 75% to 80%, while a 70% to 75% efficacy rate is considered feasible for broad distribution, though the technology allows for rapid replication of results to address quick mutation rates.
- Regulatory processes are expected to maintain high standards without cutting corners, with data presentation to the FDA and public scheduled for after peer-reviewed publication, and financial models include generating profit with volume discounts rather than a primary focus on return on investment.
- Risks include the difficulty of contact tracing if community infection spreads widely, potential political pressure to approve vaccines early based solely on immunogenicity data, and infrastructure hurdles in sorting global supply networks and government orders.
- Current spread is not being curbed by warm weather but is instead driven by human behavior, with masks and crowd avoidance expected to slow but not necessarily stop transmission, while specific travel quarantine advisories face feasibility concerns regarding their implementation.